Epidemiology aspects of inflammatory bowel disease in the east region of Minas Gerais state;Aspectos epidemiológicos das doenças intestinais inflamatórias na macrorregião de saúde leste do estado de Minas Gerais

Ciencia e Saude Coletiva

Volumn 15, Issue SUPPL. 1, 2010, Pages 1031-1037

  Oliveira, Flávia Márcia ^a   Emerick, Ana Paula do Carmo ^b   Soares, Elisângela Guimarães ^a  

^a FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

^b NONE

Author keywords

Biological factors; Epidemiology; Inflammatory bowel diseases

Indexed keywords

ARTICLE; BRAZIL; ENTERITIS; FEMALE; HUMAN; MALE;

BRAZIL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE;

EID: 78349231314     PISSN: 14138123     EISSN: 16784561     Source Type: Journal    
DOI: 10.1590/s1413-81232010000700009     Document Type: Article

References (35)

1. Pontes RWA, Miszputen SJ, Ferreira-Filho OF, Miranda C, Ferraz MB. Qualidade de vida em pacientes portadores de doença inflamatória intestinal: tradução para o português e validação do questionário "Inflammatory Bowel Disease Questionnaire" (IBDQ). Arq Gastroenterol 2004; 41(2):137-143.
2. Shanahan F. Crohn's disease. Lancet 2002; 359:62-69.
3. Van Heel DA, McGovern DPB, Jewell DP. Crohn's disease: genetic susceptibility, bacteria, and innate immunity. Lancet 2001; 441:1902-1904.
4. Van Heel DA, Udalova I, De Silva A, McGovern D, Kinouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP, Kwiatkowski D. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kB transcription factors. Hum Mol Genet 2002; 11:1281-1289.
5. Dionne S, Ruemmele FM, Seidman EG. Immunopathogenesis of inflammatory bowel disease: role of cytokines and immune cell-enterocyte interactions. In: Bristian BR, Walker-Smith JA, editors. Nestle Nutr Workshop Ser Clin Perform Programme 1999; 2:41-57.
6. Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of interleukin-1 beta, interleukin-2 and soluble interleukin-2 receptors in endoscopial mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992; 33:55-58.
7. Pullman WE, Elsbury S, Kobayashi M, Happen AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992; 102:529-537.
8. Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993; 104:1285-1292.
9. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994; 19:7-21.
10. Podolsky DK. Inflammatory Bowel Disease. N Eng J Med 2002; 347:417-429.
11. Buller H, Chin S, Kirschner B, Kohn J, Markowitz J, Moore D, Murch S, Taminiau J. Inflammatory bowel disease in children and adolescents. Working Group Report of The First World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002; 35(Suppl 2):151-158.
12. Biondo-Simões MLP, Mandelli KK, Pereira MSC, Faturi JL. Opções terapêuticas para as doenças inflamatórias intestinais: revisão. Rev Bras Coloproct 2003; 23(3):172-182.
13. Ortigosa L. Concepto actual y aspectos clínicos de la enfermedad de Crohn y la colitis ulcerosa. Colombia Médica 2005; 36(2. Supl 1):16-24.
14. Hyams JS. Enfermedad de Crohn. Clin Pediatr N Am 1996; 1:243-263.
15. Kirschner BS. Colite ulcerosa. Clin Pedriatr N Am 1996; 1:223-241.
16. Pearson C. Inflammatory bowel disease. Clinical Advanced NT 2004; 100(9):86-90.
17. Quera R, Shanahan F. Thromboembolism - an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99:1971-1973.
18. Muñoz SC, Quera RP, Jesen CB, Brahm BJ, Velasco MR, Gil LCL, Latorre RM, Madrid AMS, Lubascher JC, Valenzuela JE, Alvarez LL, Karelovic SC. Tromboembolismo, otra manifestación extraintestinal de las Enfermedades Inflamatorias Intestinales. Gastr Latinoam 2006; 17(1):13-22.
19. Moreno-Jiménez B, Blanco BL, Rodríguez-Muñoz A, Hernández EG. The influence of personality factors on health-related quality of life of patients with inflammatory bowel disease. J Psychossom Res 2007; 62:39-46.
20. Souza MALP, Troncon LEA, Rodrigues CM, Viana CFG, Onofre PHC, Monteiro RA, Passos ADC, Martinelli ALC, Meneghelli UG. Evolução da ocorrência (1980-1999) da doença de Crohn e da retocolite ulcerativa idiopática e análise das suas características em um hospital universitário do sudeste do Brasil. Arq Gastroenterol 2002; 39(2):98-105.
21. British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease. London: BSG; 2003.
22. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991; 100:350-358.
23. Irvine E, Farrokhyar F, Swarbrick ET. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001; 36:2-15.
24. Appleyard C, Hernández G, Ríos-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis 2004; 10:106-111.
25. Gaburri PD, Chebli JMF, Castro LEVV, Ferreira JOD, Lopes MHM, Ribeiro AMB, Alves RA, Froede EC, Oliveira KS, Gaburri AK, Gaburri D, Meirelles GSP, Souza AFM, Chelbi JMF. Epidemiologia, aspectos clínicos e evolutivos da doença de Crohn: estudo de 60 casos. Arq Gastroenterol 1998; 35:240-246.
26. González R. Crisis grave de enfermedad inflamatoria intestinal: diagnóstico y tratamiento. Gastr Latinoam 2004; 15(2):120-126.
27. Campos FG, Waitzberg DL, Teixeira MG, Mucerino DR, Habr-Gama A, Kiss DR. Inflammatory bowel disease. Principles of nutritional therapy. Rev Hosp Clín Fac Med S Paulo 2002; 57(4):187-198.
28. Forbes A. Medical Therapy. In: Forbes A. Clinicians guide to inflammatory bowel disease. London: Chapaman & Hall Medical; 1998.
29. Smeltzer SC, Bare BG. Tratado de enfermagem medico-cirúrgica. Rio de Janeiro: Guanabara Koogan; 2002.
30. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers L, Mekhijian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn ́s disease. Gut 1991; 32:1071-1075.
31. Turunen UM, Farkkila MA, Hakala K, Seppãlã K, Sivonen A, Ogren M, Vuoristo M, Valtoren W, Miettnen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double blind, placebo-controlled study. Gastroenterol 1998; 115:1072-1078.
32. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterol 1998; 114:15-22.
33. Veras CMT, Martins MS. A confiabilidade dos dados nos formulários de autorização de internação hospitalar (AIH), Rio de Janeiro, Brazil. Cad Saude Publica 1994; 10(3):339-355.
34. Almeida MF, Barata RB, Montero CV, Silva ZP. Prevalência de doenças crônicas auto-referidas e utilização de serviços de saúde, PNAD/1998, Brasil. Cien Saude Colet 2002; 7(4):743-756.
35. Andrade ACM, Santana GO, Santos RR, Gudes JC, Lyra LGC. Perfil da doença de Crohn fistulizante em atividade em dois serviços universitários em Salvador-Bahia. Rev Bras Coloproct 2005; 25(3):241-248.